Eli Lilly's head of obesity talks weight-loss innovations for 2025 — from an Ozempic-like pill to a triple-threat shot
Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...
Move Over Mounjaro. Eli Lilly Has Another Blockbuster Opportunity in the Making, and No One Is Talking About It.
Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has another enormous opportunity that's getting very little attention.
corporatecomplianceinsights.com3d
PE Firms Make Strategic Investment in Managed Services Provider Thrive
Berkshire Partners and Court Square Capital Partners have made a strategic investment in Thrive, a Massachusetts-based provider of cybersecurity and ...
Visa’s makes key investment in Moniepoint for African SMEs financial inclusion
Moniepoint has secured an investment from Visa (V), a global leader in digital payments. The investment marks an important milestone in Visa’s ...
Eli Lilly: Market Overreacted
Eli Lilly's diverse portfolio shows broad growth, with significant contributions from oncology and other therapeutic areas.